Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level

International Journal of Dermatology

Volumn 47, Issue 10, 2008, Pages 1011-1014

  Ctirad, Andrys ^a   Lenka, Borska ^a   David, Pohl ^a   Zdenek, Fiala ^a   Kveta, Hamakova ^a   Karel, Ettler ^a   Jan, Krejsek ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COAL TAR; PENTRAXIN 3;

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNONEPHELOMETRY; MALE; PHOTOTHERAPY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PSORIASIS VULGARIS; ULTRAVIOLET RADIATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHRONIC DISEASE; COAL TAR; FEMALE; HUMANS; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; PSORIASIS; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX; ULTRAVIOLET THERAPY; YOUNG ADULT;

EID: 54749128271     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03666.x     Document Type: Article

References (16)

1. Goeckerman WH. Treatment of psoriasis. Northwest Med 1925; 24: 229-231.
2. Jenner N, Campbell J, Plunkett A, et al. Cost of psoriasis: A study on the morbidity and financial effects of having psoriasis in Australia. Australasian J Dermatol 2002; 43: 255-261.
3. Lee E, Koo J. Modern modified "ultra" Goeckerman therapy: A PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. J Dermatologic Treat 2005; 16: 102-107.
4. Gudjonsson JE, Johnston A, Sigmundsdottir H, et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1-8.
5. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentraxin family of acute phase proteins. J Immunol 1993; 150: 1804-1812.
6. Introna M, Alles VV, Castellano M, et al. Cloning of mouse PTX3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996; 87: 1862-1872.
7. Azzuri A, Sow OY, Amedei A, et al. IFN-γ-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infection 2004; 7: 1-8.
8. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-2354.
9. Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29: 1404-1407.
10. Bevelacqua V, Libra M, Mazzarino MC, et al. Long pentraxin 3: A marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006; 18: 415-423.
11. Luchetti MM, Piccinini G, Mantovani A, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 119: 196-202.
12. Fazzini F, Dell'Antonio G, Dal Cin E, et al. PTX3 in small-vessel vasculitides: An independent indicator of disease activity produced at sites of inflammation. Arthritis Rheumatism 2001; 44: 2841-2850.
13. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-498.
14. Wisniewski HG, Vilcek J. Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 Ptx3/ TSG-14. Cytokine Growth Factor Rev 2004; 15: 129-146.
15. Leong TT, Fearon U, Veale DJ. Angiogenesis in psoriasis and psoriatic arthritis: Clues to disease pathogenesis. Curr Rheumatol Rep 2005; 7: 325-329.
16. De Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatol Ther 2004; 17: 341-349.